Tag: AML

Top antibody-drug conjugate (ADC) companies leading the industry

The antibody-drug conjugate (ADC) field is witnessing an expansion in the variety of conjugation techniques, linker chemistry, and payloads being used, moving beyond traditional tubulin inhibitors to include novel mechanisms of action. Investments in ADC research continue to grow, with significant funding rounds and acquisitions. For example, Novo Holdings’ $105…

Continue Reading Top antibody-drug conjugate (ADC) companies leading the industry

Ten NK cell therapy companies to look out for this year

Natural killer (NK) cells are white blood cells that are a part of the body’s defense mechanism. These cells are on the lookout for any kind of disruption in the immune system, and can kill diseased cells like tumor cells. NK cells are being used in clinical applications to treat…

Continue Reading Ten NK cell therapy companies to look out for this year

Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma

Vincerx Pharma, Inc. Investigators from the National Institutes of Health (NIH) report 2 partial responses (PR) in 3 peripheral T-cell lymphoma (PTCL) patients and 1 PR in 2 double-hit diffuse large b-cell lymphoma (DH-DLBCL) patients in ongoing dose-escalation trial of enitociclib in combination with venetoclax and prednisone Vincerx remains on…

Continue Reading Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma

Early prognosis prediction in acute myeloid and acute lymphoid Leukaemia patients by cell free DNA (cfDNA) Concentration Ratios

1Indian Council of Medical Research (ICMR), India 2Vardhman Mahavir Medical College & Safdarjung Hospital, India The final, formatted version of the article will be published soon. Notify me Receive an email when it is updated You just subscribed to receive the final…

Continue Reading Early prognosis prediction in acute myeloid and acute lymphoid Leukaemia patients by cell free DNA (cfDNA) Concentration Ratios

UChicago Medicine experts showcase blood cancer research at 65th ASH Annual Meeting

Faculty and trainees from the University of Chicago Medicine Comprehensive Cancer Center (UCCCC) joined the world’s largest hematology community to discuss the latest updates in blood cancers at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition held December 9-12, 2023 in San Diego and online. At the meeting,…

Continue Reading UChicago Medicine experts showcase blood cancer research at 65th ASH Annual Meeting

Promising Biotech Selling Way Under Cash Value

Nkarta is using CRISPR technology for cell therapies for leukemia. The FDA just approved a similar cell therapy treatment for Vertex using the same CRISPR technology. Nkarta is trading well below cash value and has a significant short position sinking underwater. We did very well with Talaris as a takeover…

Continue Reading Promising Biotech Selling Way Under Cash Value

Preleukemic clonal evolution revealed using single-cell DNA sequencing and computational modelling

Abstract The acquisition of cancer driver mutations can predate diagnosis by decades. However, our understanding of the evolution that occurs in these early stages of cancer remains limited because most studies focus only on sequencing the malignant clone that “wins” the evolutionary race. The representation of driver mutations in the…

Continue Reading Preleukemic clonal evolution revealed using single-cell DNA sequencing and computational modelling

PRRG4 regulates mitochondrial function and promotes migratory behaviors of breast cancer cells through the Src-STAT3-POLG axis | Cancer Cell International

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. doi.org/10.3322/caac.21660. Article  PubMed  Google Scholar  Hu G, Chong RA, Yang Q, Wei Y, Blanco…

Continue Reading PRRG4 regulates mitochondrial function and promotes migratory behaviors of breast cancer cells through the Src-STAT3-POLG axis | Cancer Cell International

MD Anderson Research Highlights for December

HOUSTON ― The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. Recent developments at…

Continue Reading MD Anderson Research Highlights for December

Seven precision medicine companies worth keeping an eye on

Precision medicine is an approach to tailoring treatments based on people’s genetic makeup, lifestyles and environment. These targeted interventions can tackle diseases like cancer, neurological as well as metabolic diseases. The global market value of the precision medicine industry, encompassing many companies, crossed 70 billion last year, and is expected…

Continue Reading Seven precision medicine companies worth keeping an eye on

Measurable Residual Disease-Guided Therapy Promising in CLL

SAN DIEGO — In untreated chronic lymphocytic leukemia (CLL), patients who received ibrutinib plus venetoclax for a duration determined by disease characteristics rather than a fixed schedule had significantly better progression-free and overall survival compared with conventional chemoimmunotherapy, a new phase 3 analysis shows. The targeted therapy combination was also…

Continue Reading Measurable Residual Disease-Guided Therapy Promising in CLL

Panel-based RNA fusion sequencing improves diagnostics of pediatric acute myeloid leukemia

Rasche M, Zimmermann M, Borschel L, Bourquin J, Dworzak M, Klingebiel T, et al. Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012. Leukemia. 2018;32:2167–77. Article  PubMed  PubMed Central  Google Scholar  Manola KN. Cytogenetics of pediatric acute…

Continue Reading Panel-based RNA fusion sequencing improves diagnostics of pediatric acute myeloid leukemia

Trem-cel a CRISPR/Cas9-Edited Allograft Devoid of CD33 Shows Rapid Engraftment in High-Risk Acute Myeloid Leukemia

Trem-cel, a CRISPR/Cas9 gene-edited allograft, demonstrated rapid primary engraftment among patients with high-risk acute myeloid leukemia (AML), according to results of a study that were presented at the ASH Annual Meeting 2023. Trem-cel (VOR33) uses CRISPR/Cas9 technology to delete CD33 in allograft tissue. It was developed to protect normal hematopoietic…

Continue Reading Trem-cel a CRISPR/Cas9-Edited Allograft Devoid of CD33 Shows Rapid Engraftment in High-Risk Acute Myeloid Leukemia

Actinium Announces Iomab-B Produces High Response Rates and Significant Improvement in Overall Survival in Relapsed Refractory AML Patients with Active Disease Overcoming TP53 Mutation

  Relapsed or refractory AML patients with TP53 mutation known to have dismal outcomes due to limited effective treatment options   Median Overall Survival of 5.49 months observed in patients with a TP53 mutation receiving an Iomab-B led allogeneic bone marrow transplant compared to 1.66…

Continue Reading Actinium Announces Iomab-B Produces High Response Rates and Significant Improvement in Overall Survival in Relapsed Refractory AML Patients with Active Disease Overcoming TP53 Mutation

City of Hope Scientists Present Promising New Research at American Society of Hematology Annual Meeting

This section is Partnership Content supplied The content in this section is supplied by Business Wire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by Business Wire Breadcrumb Trail Links PMN Press Releases Business Wire News Releases Author of the…

Continue Reading City of Hope Scientists Present Promising New Research at American Society of Hematology Annual Meeting

Is Genome Editing the Next Step in Immunotherapy Innovation? Experts Think So

Just a few years ago, chimeric antigen receptor (CAR) T-cell therapy was brand new, offering a novel solution for populations of patients who were short on options and typically faced grim prognoses. But this weekend at the American Society of Hematology Annual Meeting and Exposition, a presentation saw experts in…

Continue Reading Is Genome Editing the Next Step in Immunotherapy Innovation? Experts Think So

Real-World Data Show Oral Decitabine/Cedazuridine Regimen Is Comparable With IV/SC HMAs in MDS

“It’s hoped that [longer persistence with oral DEC-C] would translate to better outcomes because those patients are able to stay on a treatment that takes time to work,” said Amer Zeidan, MD, in a presentation during the meeting. Retrospective, real-world results showed that oral decitabine and cedazuridine (DEC-C) and standard…

Continue Reading Real-World Data Show Oral Decitabine/Cedazuridine Regimen Is Comparable With IV/SC HMAs in MDS

Improvements in Stem Cell Transplants for AML With CRISPR

Guenther Koehne, MD, PhD, deputy director and chief of blood and marrow Transplant, hematologic oncology and benign hematology, Baptist Health Medical Group, discusses a phase 1/2 study (NCT04849910) where he served as the principal investigator. The abstract is being presented at this year’s American Society of Hematology 2023 Annual Meeting….

Continue Reading Improvements in Stem Cell Transplants for AML With CRISPR

Circular RNA Associated With Higher Risk and Poor Outcomes in MDS and AML

The circular RNA (circRNA) circZBTB46 was expressed at increasing levels among patients with higher risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) and was associated with shorter survival, according to the results of a study published in the journal Clinical and Experimental Medicine. A type of noncoding, stable RNA,…

Continue Reading Circular RNA Associated With Higher Risk and Poor Outcomes in MDS and AML

Vertex compliance Latest Developer Job Openings

devjobsscanner Post a JobJobsBlog Search Search Advanced options Remote Min. Salary… Min. Date… Sort by… Vertex Fellow Oxford Vertex Pharmaceuticals Oxford, England, United Kingdom 3 weeks agofromlinkedin See offer Principal Engineer, Vertex AI Search Quality Google Sunnyvale, CA 2 weeks agofromlinkedin See offer SAP VERTEX Technical/Developer Troubleshooting Expert Denken Solutions…

Continue Reading Vertex compliance Latest Developer Job Openings

SELLAS Life Sciences Announces Positive Recommendation from REGAL Independent Data Monitoring Committee of Galinpepimut-S in Acute Myeloid Leukemia

SELLAS Life Sciences Announces Positive Recommendation from REGAL Independent Data Monitoring Committee of Galinpepimut-S in Acute Myeloid Leukemia – Independent Data Monitoring Committee (IDMC) Recommended Continuation of Phase 3 REGAL Trial Without Any Modifications – – IDMC Expressed Satisfaction with Speed of Enrollment and High Study Integrity – – IDMC…

Continue Reading SELLAS Life Sciences Announces Positive Recommendation from REGAL Independent Data Monitoring Committee of Galinpepimut-S in Acute Myeloid Leukemia

SELLAS Life Sciences Announces Positive Recommendation from

– Independent Data Monitoring Committee (IDMC) Recommended Continuation of Phase 3 REGAL Trial Without Any Modifications – – IDMC Expressed Satisfaction with Speed of Enrollment and High Study Integrity – – IDMC Will Review Most Current Survival Data at Next Scheduled IDMC Meeting in Q1 2024 – NEW YORK, Dec. 04,…

Continue Reading SELLAS Life Sciences Announces Positive Recommendation from

SELLAS Life Sciences Announces Positive Recommendation from REGAL Independent Data Monitoring Committee of Galinpepimut-S in Acute Myeloid Leukemia – SELLAS Life Sciences Gr (NASDAQ:SLS)

– Independent Data Monitoring Committee (IDMC) Recommended Continuation of Phase 3 REGAL Trial Without Any Modifications – – IDMC Expressed Satisfaction with Speed of Enrollment and High Study Integrity – – IDMC Will Review Most Current Survival Data at Next Scheduled IDMC Meeting in Q1 2024 – NEW YORK, Dec. 04,…

Continue Reading SELLAS Life Sciences Announces Positive Recommendation from REGAL Independent Data Monitoring Committee of Galinpepimut-S in Acute Myeloid Leukemia – SELLAS Life Sciences Gr (NASDAQ:SLS)

Targeting the epigenome to reinvigorate T cells for cancer immunotherapy | Military Medical Research

Tsui C, Kretschmer L, Rapelius S, Gabriel SS, Chisanga D, Knöpper K, et al. MYB orchestrates T cell exhaustion and response to checkpoint inhibition. Nature. 2022;609(7926):354–60. Article  CAS  PubMed  PubMed Central  Google Scholar  Zhu L, Zhou X, Gu M, Kim J, Li Y, Ko CJ, et al. Dapl1 controls NFATc2…

Continue Reading Targeting the epigenome to reinvigorate T cells for cancer immunotherapy | Military Medical Research

Ryvu Therapeutics Reports Third Quarter 2023 Financial

The total operating revenues amounted to $11.9M and increased by 42% compared to Q3 2022. Updated data from Phase Ib study of RVU120 in AML/HR-MDS to be presented at the upcoming American Society of Hematology (ASH) Annual Meeting in December. Preparations for executing Phase II clinical trials of RVU120 in…

Continue Reading Ryvu Therapeutics Reports Third Quarter 2023 Financial

Serial Next Generation Sequencing and the Role of PARP Inhibitor Therapy in 2024

(UroToday.com) The 2023 Society of Urologic Oncology (SUO) annual meeting held in Washington, D.C. between November 28th and December 1st, 2023, was host to a prostate cancer course. Dr. Alan Bryce provided an overview of the use and application of serial next generation sequencing (NGS) in the castrate-resistant prostate cancer disease…

Continue Reading Serial Next Generation Sequencing and the Role of PARP Inhibitor Therapy in 2024

Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy | Molecular Cancer

Rowe RG, Daley GQ. Induced pluripotent stem cells in disease modelling and drug discovery. Nat Rev Genet. 2019;20:377–88. Article  CAS  PubMed  PubMed Central  Google Scholar  Li L, Papadopoulos V. Advances in stem cell research for the treatment of primary hypogonadism. Nat Rev Urol. 2021;18:487–507. Article  CAS  PubMed  Google Scholar  Lawrence…

Continue Reading Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy | Molecular Cancer

Genomic DNA-based measurable residual disease monitoring in pediatric acute myeloid leukemia: unselected consecutive cohort study

Genetic characterization For risk stratification and identification of genetic aberrations suitable as MRD targets, diagnostic material from 133 children with primary AML was examined (see “Methods” and Supplementary Table 3). The presence of selected fusion genes and mutations was prospectively investigated using (q)RT-PCR and sequencing. A primary genetic aberration was found…

Continue Reading Genomic DNA-based measurable residual disease monitoring in pediatric acute myeloid leukemia: unselected consecutive cohort study

How did IPSC come to be?

how does aml disrupt the immune system 5 answers how does aml disrupt normal tissue functioning 5 answers what are the papers that describe the types of cancer cells? 5 answers What are the latest papers with the highest impact factor in Gene Regulatory Networks research area 5 answers What…

Continue Reading How did IPSC come to be?

‘Strongly positioned to move the business forward’: Race Oncology appoints new CEO

Race Oncology appoints former chief scientific officer and executive director Dr Daniel Tillet as CEO Independent chair Mary Harney says RAC now best positioned to deliver on its primary focus of advancing bisantrene Company releases its updated strategy including bonus options plan to fund Phase 2 efficacy studies   Special…

Continue Reading ‘Strongly positioned to move the business forward’: Race Oncology appoints new CEO

The surge in antibody drug conjugates investments

Antibody drug conjugates (ADCs) have been much sought-after through investments of late, with big pharma eyeing these drugs developed by various biotechs, to eventually nab them. With yet another ADC being bought by Bristol Myers Squibb, are these drugs the golden ticket to targeted cancer treatment? “There are very strong…

Continue Reading The surge in antibody drug conjugates investments

Research Fellow, School of Medicine job with QUEENS UNIVERSITY BELFAST

Job reference: 23/111420 Date posted: 20/11/2023 Application closing date: 11/12/2023 Salary: £37,841 per annum Job category/type: Research The School of Medicine, Dentistry & Biomedical Sciences (MDBS) at Queen’s University Belfast, is currently seeking to appoint an exceptional candidate to the post of Research Fellow to work on a Leukaemia and Lymphoma NI (LLNI) funded project focused on…

Continue Reading Research Fellow, School of Medicine job with QUEENS UNIVERSITY BELFAST

CAR-NK cells: promising for cancer therapy

The suitability of NK cells for cancer therapy has been challenged by some investor and business interests because of limited efficacy data, is this a valid belief at the present stage of development of the immune therapy field? NK cells are among the front line of protection from infected and…

Continue Reading CAR-NK cells: promising for cancer therapy

Using Genomic Profiling to Provide Personalized Medicine in MDS

Myelodysplastic syndromes (MDS) is a group of clonal hematopoietic neoplasms characterized by the combination of persistent unexplained cytopenia (or cytopenias) and morphologic dysplasia and a propensity to progress to bone marrow failure or acute myeloid leukemia (AML).1 The treatment landscape for MDS is continually progressing and involves a multidisciplinary approach…

Continue Reading Using Genomic Profiling to Provide Personalized Medicine in MDS

Looking good for cancer therapy

The suitability of NK cells for cancer therapy has been challenged by some investor and business interests because of limited efficacy data, but is this belief at the present stage of development of the immune therapy field? NK cells are among the front line of protection from infected and abnormal…

Continue Reading Looking good for cancer therapy

gene therapy pioneer to biotech rebuff?

Once thought to be a frontrunner in gene therapy, uniQure’s fame may no longer be coveted, as the biotech looks to reorganize by slashing its workforce, in an attempt to stay afloat. But how did things go awry for the company that was once in its prime in the DNA…

Continue Reading gene therapy pioneer to biotech rebuff?

Novel Assay May Help Detect and Treat Patients With AML

By The ASCO Post StaffPosted: 11/15/2023 10:20:00 AM Last Updated: 11/15/2023 11:37:35 AM A novel assay may be effective at detecting a unique molecular marker in patients with acute myeloid leukemia (AML), according to a recent study published by Young et al in The Journal of Molecular Diagnostics. The new…

Continue Reading Novel Assay May Help Detect and Treat Patients With AML

New assay could revolutionize detection and treatment of acute myeloid leukemia

Design of droplet digital PCR (ddPCR) assay. A: Schematic of ddPCR assay. Primers spanned the fusion break points (KMT2A-AF4 depicted). Nested fluorescently labeled probes recognized unique sequences in KMT2A (FAM) and the fusion partner AFF1-AF4 (HEX). B: Example ddPCR result depicting double-positive droplets containing cDNA with an oncogenic KMT2A fusion…

Continue Reading New assay could revolutionize detection and treatment of acute myeloid leukemia

Myeloid/Lymphoid Neoplasms with ETV6::PDGFRB Fusion Gene

Introduction The ETV6::PDGFRB fusion gene is commonly associated with myeloid neoplasms with monocytosis (such as CMML), and with eosinophilia.1 The PDGFRB gene, located on 5q33, encodes PDGFRβ, a type III tyrosine kinase comprising an extracellular domain consisting of five immunoglobulin (Ig)-like domains, a single-transmembrane helix domain, a juxtamembrance domain, and…

Continue Reading Myeloid/Lymphoid Neoplasms with ETV6::PDGFRB Fusion Gene

Post-doctoral fellow (Bioinformatics) | Thijssen lab, Amsterdam

Post-doctoral fellow (Bioinformatics): We are seeking a motivated and enthusiastic bioinformatician to join the Thijssen lab, contributing to cutting-edge research in the field of Acute Myeloid Leukemia (AML). This position offers a unique opportunity to delve into the molecular basis of leukemia cell plasticity and drug resistance, with a focus…

Continue Reading Post-doctoral fellow (Bioinformatics) | Thijssen lab, Amsterdam

Latent human herpesvirus 6 is reactivated in CAR T cells

Spanjaart, A. M., van der Valk, F. M., van Rooijen, G., Brouwer, M. C. & Kersten, M. J. Confused about confusion. N. Engl. J. Med. 386, 80–87 (2022). Article  PubMed  Google Scholar  Haradhvala, N. J. et al. Distinct cellular dynamics associated with response to CAR-T therapy for refractory B-cell lymphoma….

Continue Reading Latent human herpesvirus 6 is reactivated in CAR T cells

Leukaemia Foundation, HSANZ Fund Future Clinicians to Boost Aussie Survival Rates

The Leukaemia Foundation and Haematology Society of Australia and New Zealand (HSANZ) have again partnered to award three of Australia’s brightest blood cancer researchers and clinicians with PhD scholarships. The 2023 recipients were announced last night at the annual Blood conference in Melbourne and include Dr Helen Cashman, Dr Eric…

Continue Reading Leukaemia Foundation, HSANZ Fund Future Clinicians to Boost Aussie Survival Rates

Racial Disparities in the Genetic Landscape of Acute Myeloid Leukaemia from The Cancer Genome Atlas: Insights from a Bioinformatics Analysis

Abstract Acute myeloid leukaemia (AML) is a heterogeneous disease with complex pathogenesis that affects hematopoietic stem cells. Ethnic and racial disparities have been reported to affect treatment and survival outcomes in AML patients. Here, we analysed clinical and transcriptomic data from The Cancer Genome Atlas (TCGA) to investigate potential differences…

Continue Reading Racial Disparities in the Genetic Landscape of Acute Myeloid Leukaemia from The Cancer Genome Atlas: Insights from a Bioinformatics Analysis

Stanford to use Sequentify kits for Hematological Malignancies NGS Sequencing

REHOVOT, Israel, Nov. 8, 2023 /PRNewswire/ — Sequentify, a Weizmann Institute spinoff that develops synthetic biology and AI software to enable rapid targeted DNA sequencing, is pleased to announce Stanford Institute for Stem Cell Biology and Regenerative Medicine will be using its NGS targeted panels for acute myeloid leukemia (AML)…

Continue Reading Stanford to use Sequentify kits for Hematological Malignancies NGS Sequencing

Insights gained from single-cell analysis of chimeric antigen receptor T-cell immunotherapy in cancer | Military Medical Research

Zhu J, Ke Y, Liu Q, Yang J, Liu F, Xu R, et al. Engineered Lactococcus lactis secreting Flt3L and OX40 ligand for in situ vaccination-based cancer immunotherapy. Nat Commun. 2022;13(1):7466. Article  CAS  PubMed  PubMed Central  Google Scholar  Evans ER, Bugga P, Asthana V, Drezek R. Metallic nanoparticles for cancer…

Continue Reading Insights gained from single-cell analysis of chimeric antigen receptor T-cell immunotherapy in cancer | Military Medical Research

2023-11-07 | NDAQ:VOR | Press Release

Next trem-cel (VOR33) clinical data update expected by Relapse After Transplant and Cellular Therapy (HSCT2) Conference Nov 10-11 Three oral abstracts and two poster presentations accepted at ASH 2023 Dec 9-12 CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company,…

Continue Reading 2023-11-07 | NDAQ:VOR | Press Release

Genetics and epidemiology of mutational barcode-defined clonal hematopoiesis

Identification of CH cases from WGS in ISL and UKB We used WGS from 45,510 Icelanders and 130,709 British ancestry participants from the UKB17,18. Average sequencing depth was 33× for UKB and 38× for ISL. Participants with prior diagnoses of hematological disorders or grossly abnormal hematology measurements on entry were…

Continue Reading Genetics and epidemiology of mutational barcode-defined clonal hematopoiesis

Geron Corporation Eyes $3.5 Billion Opportunity in MDS and MF Treatment Market By Investing.com

© Reuters. Geron (NASDAQ:) Corporation (NASDAQ:GERN) has updated its progress and plans during its third quarter 2023 earnings conference call, highlighting the potential of its drug imetelstat for the treatment of lower-risk myelodysplastic syndromes (MDS) and myelofibrosis (MF). The company has submitted a New Drug Application (NDA) for imetelstat, which…

Continue Reading Geron Corporation Eyes $3.5 Billion Opportunity in MDS and MF Treatment Market By Investing.com

Leveraging GPT-4 for Rapid Data Processing and Machine Learning on Kaggle Datasets | by Purvil Patel | Nov, 2023

In the age of data, having the skills to process, analyze, and derive insights from vast amounts of information is crucial. However, the process can often be time-consuming, especially with the variety and complexity of datasets available. This article delves into the journey of harnessing the power of GPT-4’s code…

Continue Reading Leveraging GPT-4 for Rapid Data Processing and Machine Learning on Kaggle Datasets | by Purvil Patel | Nov, 2023

Genmab Announces Multiple Abstracts to be Presented at the 65th Annual Meeting and Exposition of the American Society of Hematology (ASH)

Genmab A/S Media Release COPENHAGEN, Denmark; November 2, 2023 Eighteen total abstracts accepted for presentation and publication, including results from four clinical trials evaluating epcoritamab in multiple treatment settings and patient populations Oral presentations highlighting new findings from a clinical trial of epcoritamab in patients with relapsed/refractory (R/R) diffuse large…

Continue Reading Genmab Announces Multiple Abstracts to be Presented at the 65th Annual Meeting and Exposition of the American Society of Hematology (ASH)

CRISPR/Cas9 bioluminescence-based assay for monitoring CFTR trafficking to the plasma membrane

Introduction Cystic fibrosis (CF) is a lethal, autosomal recessive disorder caused by mutations in the CFTR gene that results in aberrant transport of chloride, bicarbonate, and sodium ions (Kerem et al, 1989; Riordan et al, 1989; Rommens et al, 1989; Tabcharani et al, 1991; Poulsen et al, 1994; Stutts et…

Continue Reading CRISPR/Cas9 bioluminescence-based assay for monitoring CFTR trafficking to the plasma membrane

FDA Grants Fast Track Designation to SLS009 for Relapsed/Refractory PTCL

The FDA has granted a fast track designation to SLS009 (formerly GFH009) for the treatment of patients with relapsed/refractory peripheral T-cell lymphoma (PTCL), according to an announcement from SELLAS Life Sciences Group.1 The fast track designation follows the readout of topline data from a phase 1 trial (NCT04588922), which showed…

Continue Reading FDA Grants Fast Track Designation to SLS009 for Relapsed/Refractory PTCL

Discovery unlocks potential new arsenal to target leukemia and other cancers

Integrative analysis of samples from patients with AML. a, Unsupervised hierarchical clustering analysis on the expression of 300 transcripts with the greatest variance-to-mean ratios among 30 individual AMLs from our repository that can successfully generate AML PDX. MLD, multi-lineage dysplasia; MDS, myelodysplastic syndromes; MLL, mixed-lineage leukemia; NOS, not otherwise specified….

Continue Reading Discovery unlocks potential new arsenal to target leukemia and other cancers

Design, optimization, production and activity testing of recombinant immunotoxins expressed in plants and plant cells for the treatment of monocytic leukemia

. 2023 Dec;14(1):2244235. doi: 10.1080/21655979.2023.2244235. Affiliations Expand Affiliations 1 Bioprocess Engineering, Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Aachen, Germany. 2 Institute for Molecular Biotechnology, RWTH Aachen University, Aachen, Germany. 3 University of Natural Resources and Life Sciences, Vienna (BOKU), Department of Biotechnology (DBT), Institute of Bioprocess Science…

Continue Reading Design, optimization, production and activity testing of recombinant immunotoxins expressed in plants and plant cells for the treatment of monocytic leukemia

T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome

Hedrick, S. M., Cohen, D. I., Nielsen, E. A. & Davis, M. M. Isolation of cDNA clones encoding T cell-specific membrane-associated proteins. Nature 308, 149–153 (1984). Article  CAS  PubMed  Google Scholar  Yanagi, Y. et al. A human T cell-specific cDNA clone encodes a protein having extensive homology to immunoglobulin chains….

Continue Reading T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome

How to find OS duration, status information of patients in GSE1159 or GSE6891 (Microarray data analysis)

How to find OS duration, status information of patients in GSE1159 or GSE6891 (Microarray data analysis) 0 Hello. I want to analyze the survival of AML patients in GSE1159 and GSE6891. However, the datasets for these series do not have survival data (OS, status). Many papers have shown survival curves…

Continue Reading How to find OS duration, status information of patients in GSE1159 or GSE6891 (Microarray data analysis)

Final Multivariate Analysis from the Phase 3 MAGNITUDE Study Shows Trend Toward Improvement in Overall Survival in Patients with mCRPC with BRCA Alterations Treated with Niraparib and Abiraterone Acetate Plus Prednisone

Niraparib and abiraterone acetate plus prednisone combination therapy also showed clinically relevant improvement versus standard of care in time to symptomatic progression and time to cytotoxic chemotherapy MADRID, Oct. 22, 2023 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the final analysis (FA) of…

Continue Reading Final Multivariate Analysis from the Phase 3 MAGNITUDE Study Shows Trend Toward Improvement in Overall Survival in Patients with mCRPC with BRCA Alterations Treated with Niraparib and Abiraterone Acetate Plus Prednisone

SELLAS Life Sciences Provides Update on Phase 3 REGAL Clinical Trial for Galinpepimut-S in … | News

– Enrollment ex-China Expected to be Completed in November 2023 – – Enrollment in China Expected to Commence this Quarter – NEW YORK, Oct. 12, 2023 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of…

Continue Reading SELLAS Life Sciences Provides Update on Phase 3 REGAL Clinical Trial for Galinpepimut-S in … | News

SELLAS Life Sciences Provides Update on Phase 3 REGAL

– Enrollment ex-China Expected to be Completed in November 2023 – – Enrollment in China Expected to Commence this Quarter – NEW YORK, Oct. 12, 2023 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of…

Continue Reading SELLAS Life Sciences Provides Update on Phase 3 REGAL

SELLAS Life Sciences (SLS) Provides Update on Phase 3 REGAL Clinical Trial for Galinpepimut-S

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today provided an update on its Phase 3 open-label registrational clinical trial (the REGAL study) for galinpepimut-S (GPS) in patients…

Continue Reading SELLAS Life Sciences (SLS) Provides Update on Phase 3 REGAL Clinical Trial for Galinpepimut-S

Bioconductor BulkRNAseq

Comment: deseq2 filter the low counts by Michael Love 40k You can’t filter the groups separately, you need to use a non-specific filter that doesn’t make use of information about which samples are … Comment: deseq2 filter the low counts by daiane.hemerichbrennan • 0 Hi Michael, I have another question…

Continue Reading Bioconductor BulkRNAseq

GenFleet Starts Phase Ib/II Trial of GFH009 (Highly Selective CDK9 Inhibitor) Treating Patients with Relapsed/Refractory Peripheral T-cell Lymphomas (PTCL)

SHANGHAI, Oct. 10, 2023 /PRNewswire/ — GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the first subject was dosed in a phase Ib/II trial of GFH009 (a highly selective CDK9 inhibitor) treating relapsed/refractory PTCL (peripheral T-cell lymphomas) patients. Designed to enroll…

Continue Reading GenFleet Starts Phase Ib/II Trial of GFH009 (Highly Selective CDK9 Inhibitor) Treating Patients with Relapsed/Refractory Peripheral T-cell Lymphomas (PTCL)

a database of gene-disease associations

rs377577594 A 0.710 CausalMutation CLINVAR Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 26619011 2016 rs377577594 0.710 GeneticVariation BEFREE We took advantage of DNMT3A (R882C) mutation-carrying AML cell strain, that is, OCI-AML3, assessing its migration ability in vitro and in vivo. 27724883 2016 rs377577594 A 0.710…

Continue Reading a database of gene-disease associations

Foghorn Therapeutics to Present Clinical and Pre-Clinical Data from Multiple Programs Across Its Diverse Pipeline at AACR-NCI-EORTC International Conference

Pre-clinical data for selective EP300 supports opportunity in solid and hematologic tumor types FHD-286, a potent, selective inhibitor of BRG1 and BRM, shows potential as a broad-based differentiation agent in both clinical and pre-clinical studies in multiple tumor types CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) — Foghorn® Therapeutics Inc. (Nasdaq:…

Continue Reading Foghorn Therapeutics to Present Clinical and Pre-Clinical Data from Multiple Programs Across Its Diverse Pipeline at AACR-NCI-EORTC International Conference

AbbVie Presents Results from Phase 3 CANOVA Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma | Small Molecules

AbbVie Presents Results from Phase 3 CANOVA Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma Details Category: Small Molecules Published on Saturday, 30 September 2023 10:46 Hits: 112 CANOVA study evaluated venetoclax plus dexamethasone in patients with t(11;14)-positive multiple myeloma compared to pomalidomide plus dexamethasone …

Continue Reading AbbVie Presents Results from Phase 3 CANOVA Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma | Small Molecules

AbbVie Presents Results from Phase 3 CANOVA Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma

CANOVA study evaluated venetoclax plus dexamethasone in patients with t(11;14)-positive multiple myeloma compared to pomalidomide plus dexamethasone Results are being presented at the International Myeloma Society Annual Meeting in Athens, Greece AbbVie will discuss the data with health authorities in the near future to further understand the…

Continue Reading AbbVie Presents Results from Phase 3 CANOVA Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma

Phase 3 Study Shows Promising Results for Venetoclax Combination Therapy in Multiple Myeloma

As of September 29, 2023, AbbVie conducted a Phase 3 study called CANOVA to assess the effectiveness and safety of a combination treatment involving venetoclax and dexamethasone for patients with relapsed or refractory multiple myeloma who have a specific genetic mutation (t(11;14)-positive) and have undergone two or more prior treatments….

Continue Reading Phase 3 Study Shows Promising Results for Venetoclax Combination Therapy in Multiple Myeloma

Illumina Oncology – Whole-genome sequencing (WGS) in acute myeloid leukemia (AML)

Illumina Oncology – Whole-genome sequencing (WGS) in acute myeloid leukemia (AML) 26 September 2023 Eric Duncavage, MD, explains how patients with AML can benefit from whole-genome sequencing testing at diagnosis and after treatment for minimal or measurable residual disease (MRD) assessment. Dr. Duncavage is the director of the sections of…

Continue Reading Illumina Oncology – Whole-genome sequencing (WGS) in acute myeloid leukemia (AML)

Gilead Discontinues Phase 3 ENHANCE-2 Trial of Magrolimab Plus Azacitidine in TP53-Mutant AML

Gilead Discontinues Phase 3 ENHANCE-2 Trial | Image Credit: ©freshidea – stock.adobe.com The phase 3 ENHANCE-2 trial (NCT04778397) examining the frontline combination of magrolimab and azacitidine (Vidaza) vs physician’s choice of venetoclax (Venclexta) with azacitidine or intensive chemotherapy in patients with acute myeloid leukemia and TP53 mutations has been discontinued,…

Continue Reading Gilead Discontinues Phase 3 ENHANCE-2 Trial of Magrolimab Plus Azacitidine in TP53-Mutant AML

Data visualisation: past, present and future

Data visualisation: past, present and future Qlucore is a leading provider of new generation bioinformatics software for research, and precision and companion diagnostics. Founded in 2007 by scientists inspired to simplify the process of data analysis for researchers, the company has worked with a number of Universities and European bodies…

Continue Reading Data visualisation: past, present and future

Mission Bio Announces and Launches Single-Cell Measurable Residual Disease (MRD) Assay –

What You Should Know: Mission Bio, a leader in single-cell multi-omic solutions for precision medicine, announced the commercial launch of the Tapestri® Single-cell MRD (scMRD) AML Multiomics Assay. The company designed the scMRD AML Multiomics Assay to bring unprecedented resolution to disease relapse and recurrence in acute myeloid leukemia (AML), demonstrating the…

Continue Reading Mission Bio Announces and Launches Single-Cell Measurable Residual Disease (MRD) Assay –

Pemmaraju Discusses Development of Targeted Therapy for BPDCN

Naveen Pemmaraju, MD Associate Professor, Department of Leukemia Division of Cancer Medicine The University of Texas MD Anderson Cancer Center Houston, TX CASE SUMMARY A man aged 67 years was referred from a dermatologist. Referred initially to dermatologist for progressive, persistent, cutaneous nodules that patient first noticed 3 weeks prior…

Continue Reading Pemmaraju Discusses Development of Targeted Therapy for BPDCN

Workshop Azure Machine Learning and PyTorch

{“payload”:{“allShortcutsEnabled”:false,”fileTree”:{“”:{“items”:[{“name”:”.github”,”path”:”.github”,”contentType”:”directory”},{“name”:”labs”,”path”:”labs”,”contentType”:”directory”},{“name”:”src”,”path”:”src”,”contentType”:”directory”},{“name”:”.gitignore”,”path”:”.gitignore”,”contentType”:”file”},{“name”:”.stats_timestamp”,”path”:”.stats_timestamp”,”contentType”:”file”},{“name”:”CODE_OF_CONDUCT.md”,”path”:”CODE_OF_CONDUCT.md”,”contentType”:”file”},{“name”:”LICENSE”,”path”:”LICENSE”,”contentType”:”file”},{“name”:”README.md”,”path”:”README.md”,”contentType”:”file”},{“name”:”SECURITY.md”,”path”:”SECURITY.md”,”contentType”:”file”},{“name”:”SUPPORT.md”,”path”:”SUPPORT.md”,”contentType”:”file”}],”totalCount”:10}},”fileTreeProcessingTime”:5.687012,”foldersToFetch”:[],”reducedMotionEnabled”:null,”repo”:{“id”:505568272,”defaultBranch”:”main”,”name”:”workshop-aml-pytorch”,”ownerLogin”:”microsoft”,”currentUserCanPush”:false,”isFork”:false,”isEmpty”:false,”createdAt”:”2022-06-20T19:13:40.000Z”,”ownerAvatar”:”avatars.githubusercontent.com/u/6154722?v=4″,”public”:true,”private”:false,”isOrgOwned”:true},”symbolsExpanded”:false,”treeExpanded”:true,”refInfo”:{“name”:”main”,”listCacheKey”:”v0:1655752422.481336″,”canEdit”:false,”refType”:”branch”,”currentOid”:”64614bd7782f10517f653397dff451aa0a005d15″},”path”:”README.md”,”currentUser”:null,”blob”:{“rawLines”:null,”stylingDirectives”:null,”csv”:null,”csvError”:null,”dependabotInfo”:{“showConfigurationBanner”:false,”configFilePath”:null,”networkDependabotPath”:”/microsoft/workshop-aml-pytorch/network/updates”,”dismissConfigurationNoticePath”:”/settings/dismiss-notice/dependabot_configuration_notice”,”configurationNoticeDismissed”:null,”repoAlertsPath”:”/microsoft/workshop-aml-pytorch/security/dependabot”,”repoSecurityAndAnalysisPath”:”/microsoft/workshop-aml-pytorch/settings/security_analysis”,”repoOwnerIsOrg”:true,”currentUserCanAdminRepo”:false},”displayName”:”README.md”,”displayUrl”:”github.com/microsoft/workshop-aml-pytorch/blob/main/README.md?raw=true”,”headerInfo”:{“blobSize”:”2.58 KB”,”deleteInfo”:{“deleteTooltip”:”You must be signed in to make or propose changes”},”editInfo”:{“editTooltip”:”You must be signed in to make or propose changes”},”ghDesktopPath”:”desktop.github.com”,”gitLfsPath”:null,”onBranch”:true,”shortPath”:”e19acfb”,”siteNavLoginPath”:”/login?return_to=https%3A%2F%2Fgithub.com%2Fmicrosoft%2Fworkshop-aml-pytorch%2Fblob%2Fmain%2FREADME.md”,”isCSV”:false,”isRichtext”:true,”toc”:[{“level”:1,”text”:”Workshop Azure Machine Learning and PyTorch”,”anchor”:”workshop-azure-machine-learning-and-pytorch”,”htmlText”:”Workshop Azure Machine Learning and PyTorch”},{“level”:3,”text”:”Labs”,”anchor”:”labs”,”htmlText”:”Labs”},{“level”:2,”text”:”Contributing”,”anchor”:”contributing”,”htmlText”:”Contributing”},{“level”:2,”text”:”Trademarks”,”anchor”:”trademarks”,”htmlText”:”Trademarks”}],”lineInfo”:{“truncatedLoc”:”36″,”truncatedSloc”:”25″},”mode”:”file”},”image”:false,”isCodeownersFile”:null,”isPlain”:false,”isValidLegacyIssueTemplate”:false,”issueTemplateHelpUrl”:”docs.github.com/articles/about-issue-and-pull-request-templates”,”issueTemplate”:null,”discussionTemplate”:null,”language”:”Markdown”,”languageID”:222,”large”:false,”loggedIn”:false,”newDiscussionPath”:”/microsoft/workshop-aml-pytorch/discussions/new”,”newIssuePath”:”/microsoft/workshop-aml-pytorch/issues/new”,”planSupportInfo”:{“repoIsFork”:null,”repoOwnedByCurrentUser”:null,”requestFullPath”:”/microsoft/workshop-aml-pytorch/blob/main/README.md”,”showFreeOrgGatedFeatureMessage”:null,”showPlanSupportBanner”:null,”upgradeDataAttributes”:null,”upgradePath”:null},”publishBannersInfo”:{“dismissActionNoticePath”:”/settings/dismiss-notice/publish_action_from_dockerfile”,”dismissStackNoticePath”:”/settings/dismiss-notice/publish_stack_from_file”,”releasePath”:”/microsoft/workshop-aml-pytorch/releases/new?marketplace=true”,”showPublishActionBanner”:false,”showPublishStackBanner”:false},”renderImageOrRaw”:false,”richText”:” \n In this hands-on lab you are going to build and deploy your own trained vision model to a highly…

Continue Reading Workshop Azure Machine Learning and PyTorch

Fast and sensitive validation of fusion transcripts in whole-genome sequencing data | BMC Bioinformatics

Al-Salama ZT, Keam SJ. Entrectinib: first global approval. Drugs. 2019;79(13):1477–83. Article  PubMed  Google Scholar  Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J…

Continue Reading Fast and sensitive validation of fusion transcripts in whole-genome sequencing data | BMC Bioinformatics

Inhibition of PLK4 remodels histone methylation and activates immune response via cGAS-STING pathway in TP53 mutated AML | Blood

Citation Cheuk Him Man, Wing Lam, Chee Chean Dang, Xiao-yuan Zeng, Li-Chuan Zheng, Natalie Nok-Man Chan, Nelson K. L. Ng, Koon-Chuen Chan, Tsz-Ho Kwok, Timothy Chi-Chun Ng, Wing Yan Leung, Michael Huen, Carmen Chak-Lui Wong, Chi Wai Eric So, Zhixun Dou, Susumu Goyama, Mark Robert Bray, Tak Wah Mak, Anskar…

Continue Reading Inhibition of PLK4 remodels histone methylation and activates immune response via cGAS-STING pathway in TP53 mutated AML | Blood

Hugo_Symbol to Entrez ID

Hello, I have Myeloid-Acute Myeloid Leukemia (AML) RNAseq data file data_mrna_seq_rpkm.csv. This file has Hugo_Symbols for all 22,844 genes but not its Entrez IDs. I was able use to two methods in R programming 1) library(org.Hs.eg.db) mapIDs method and 2) biomaRT method to get the entrez_ID of only 16,569 genes…

Continue Reading Hugo_Symbol to Entrez ID

7 Top Gene-Editing Stocks to Buy | Investing

Gene therapy and gene editing are on the cutting edge of modern biotechnology. Gene therapies are used to correct genetic abnormalities by introducing genetic material at a cellular level and can often take the form of adding a functioning copy of a gene. Gene editing takes the science to the…

Continue Reading 7 Top Gene-Editing Stocks to Buy | Investing

Baylor College of Medicine recognizes research excellence with DeBakey Awards

Six Baylor College of Medicine faculty members were selected as recipients of the 2023 Michael E. DeBakey Excellence in Research Award. They were honored at a ceremony at Baylor Sept. 18, where they each presented a talk about the work for which they were recognized. Group photo of the award…

Continue Reading Baylor College of Medicine recognizes research excellence with DeBakey Awards

A biobank of pediatric patient-derived-xenograft models in cancer precision medicine trial MAPPYACTS for relapsed and refractory tumors

Patient characteristics and PDX establishment Between February 2016 and July 2020, 787 pediatric, adolescent and young adult patients with recurrent or refractory malignancies were enrolled in the MAPPYACTS trial;2 756 (96%) patients and their parents consented to the optional ancillary study of preclinical model development (Fig. 1a). 744 patients had a…

Continue Reading A biobank of pediatric patient-derived-xenograft models in cancer precision medicine trial MAPPYACTS for relapsed and refractory tumors

Quizartinib Recommended for Approval in EU by CHMP for Patients with Newly Diagnosed FLT3-ITD Positive AML

TOKYO & MUNICH, September 15, 2023–(BUSINESS WIRE)–Daiichi Sankyo (TSE: 4568) announced that quizartinib has been recommended for approval in the European Union (EU) in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by quizartinib single-agent maintenance therapy, for adult patients with newly diagnosed acute myeloid…

Continue Reading Quizartinib Recommended for Approval in EU by CHMP for Patients with Newly Diagnosed FLT3-ITD Positive AML

Ryvu Therapeutics’ Global Licensee Menarini to Expand Development of MEN1703 (SEL24) with a New Study in Advanced Diffuse Large B-Cell Lymphoma (DLBCL)

–  Phase II Study to be Initiated in H1 2024 KRAKÓW, Poland , Sept. 14, 2023 /PRNewswire/ — Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, today announced that Ryvu’s licensee, the Menarini Group, will…

Continue Reading Ryvu Therapeutics’ Global Licensee Menarini to Expand Development of MEN1703 (SEL24) with a New Study in Advanced Diffuse Large B-Cell Lymphoma (DLBCL)

Wright’s staining for accurate diagnosis of leukemia

Introduction Leukemia, a generic term, encompasses several life threatening malignant disorders that present with incremental amounts of leucocytes in blood and bone marrow. Leukemia cells have the innate ability for migration and invasion.1 Dedifferentiated and malignant leucocytes not only retain the benign leucocytes capacity for cell motility and survival in…

Continue Reading Wright’s staining for accurate diagnosis of leukemia

Distinct N7-methylguanosine profiles of circular RNAs in drug-resistant acute myeloid leukemia

Drug-resistant AML cells display distinct cytogenetic and molecular characteristics, mainly resulting from the deletion or activation of multiple pathways associated with drug resistance3. A key contributor to drug resistance in cancer is m7G, which is recognized as a specific type of methylation pathway10. Notably, the quantity of m7G sites in…

Continue Reading Distinct N7-methylguanosine profiles of circular RNAs in drug-resistant acute myeloid leukemia

Is It Time to Bring Back the French American British Classification System?

WBCs | Image Credit: © Катерина Євтехова – www.stock.adobe.com Morphological classification systems have fallen from favor in the field of acute myeloid leukemia (AML). But with the possibility that venetoclax (Venclexta)-based regimens are less effective in patients with monocytic AML, do we need to resuscitate the French American British (FAB)…

Continue Reading Is It Time to Bring Back the French American British Classification System?

I-Mab’s Phase 3 Trial of Growth Hormone Deficiency Drug Meets Primary Endpoint, Joint Venture Partner Says -Today at 06:11 am| MarketScreener

I-Mab is a China-based company mainly engaged in the development of innovative global biotechnology. The Company’s main businesses include engaging in track record in innovation, developing innovative drug candidates and conduct clinical validation of the assets and commercialization. The Company’s pipeline is composed of ten clinical-stage assets and ten preclinical…

Continue Reading I-Mab’s Phase 3 Trial of Growth Hormone Deficiency Drug Meets Primary Endpoint, Joint Venture Partner Says -Today at 06:11 am| MarketScreener

Epitope editing enables targeted immunotherapy of acute myeloid leukaemia

Sleeping Beauty transgene overexpression Bidirectional Sleeping Beauty plasmids encoding the codon-optimized cDNA of the gene of interest (FLT3, KIT, CD123) or their mutated variants were cloned downstream of an EEF1A1 promoter. The same construct included a reporter cassette comprising a fluorescent protein (mCherry or mTagBFP2 for FLT3 and KIT, respectively)…

Continue Reading Epitope editing enables targeted immunotherapy of acute myeloid leukaemia

MD Anderson Research Highlights for August 30, 2023

Newswise — HOUSTON ― The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. Recent…

Continue Reading MD Anderson Research Highlights for August 30, 2023

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

In Nature, researchers at Boston Children’s Hospital, Dana-Farber Cancer Institute, and elsewhere outline a strategy for more precisely targeting acute myeloid leukemia with immunotherapy. With the help of optimized CRISPR-Cas9 editing of donor CD34-positive hematopoietic stem/progenitor cells (HSPCs), the team tweaked immunotherapy-targeted epitopes that are also present in normal blood…

Continue Reading Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

RefSeq: NP_001154929

LOCUS NP_001154929 155 aa linear ROD 03-MAY-2023 DEFINITION core-binding factor subunit beta isoform 3 [Mus musculus]. ACCESSION NP_001154929 VERSION NP_001154929.1 DBSOURCE REFSEQ: accession NM_001161457.1 KEYWORDS RefSeq. SOURCE Mus musculus (house mouse) ORGANISM Mus musculus Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae; Murinae; Mus;…

Continue Reading RefSeq: NP_001154929

REGAL Trial Examining Galinpepimut-S in AML to Continue Without Modifications

Angelos Stergiou, MD, ScDhc An independent data monitoring committee (IDMC) has recommended that the phase 3 REGAL trial (NCT04229979) evaluating galinpepimut-S in patients with acute myeloid leukemia (AML) should continue without modifications.1 The recommendation follows a routine, prespecified risk-benefit assessment of unblinded data collected from the study. Although event driven…

Continue Reading REGAL Trial Examining Galinpepimut-S in AML to Continue Without Modifications

An Inflammatory State Remodels the Immune Microenvironment and Improves Risk Stratification in Acute Myeloid Leukemia

About the webinar   Acute myeloid leukemia (AML) is a hematopoietic malignancy with poor prognosis and limited treatment options. Here we provide a comprehensive census of the bone marrow immune microenvironment in adult and pediatric AML patients. We characterize unique inflammation signatures in a subset of AML patients associated with…

Continue Reading An Inflammatory State Remodels the Immune Microenvironment and Improves Risk Stratification in Acute Myeloid Leukemia

Multiparameter prediction of myeloid neoplasia risk

Data acquisition UKB is a large-scale biomedical database and research resource containing genetic, lifestyle and health information from half a million UK participants. UKB has approval from the North West Multicentre Research Ethics Committee (11/NW/0382) and all participants provided written informed consent. The present study has been conducted under approved…

Continue Reading Multiparameter prediction of myeloid neoplasia risk

US FDA places partial clinical hold on Gilead’s studies on Magrolimab for AML treatment

The FDA action follows the previously announced discontinuation of the Phase 3 ENHANCE study of magrolimab in higher-risk myelodysplastic syndromes Representational image Gilead Sciences announced that the US Food and Drug Administration (FDA) has placed a partial clinical hold on the initiation of new patients in US studies evaluating magrolimab…

Continue Reading US FDA places partial clinical hold on Gilead’s studies on Magrolimab for AML treatment

Positive Feedback from IDMC for SELLAS Life Sciences Groups Phase 3 REGAL Clinical Trial of GPS in AML

SELLAS Life Sciences Group, Inc. has recently received positive feedback from the Independent Data Monitoring Committee (IDMC) regarding their ongoing Phase 3 REGAL clinical trial of galinpepimut-S (GPS) in acute myeloid leukemia (AML). The IDMC, after conducting a routine risk-benefit assessment of unblinded data, has recommended that the trial continue…

Continue Reading Positive Feedback from IDMC for SELLAS Life Sciences Groups Phase 3 REGAL Clinical Trial of GPS in AML

MD Anderson Research Highlights for August 16, 2023

Newswise — HOUSTON ― The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. Recent…

Continue Reading MD Anderson Research Highlights for August 16, 2023

In vivo screening characterizes chromatin factor functions during normal and malignant hematopoiesis

Mouse models C57BL/6J (strain 000664, The Jackson Laboratory) and B6J.129(Cg)-Gt(ROSA)26Sortm1.1(CAG-cas9*/-EGFP)Fezh/J (strain no. 026179, The Jackson Laboratory) were used for all experimental procedures. The Npm1c/Flt3-ITD/Cas9 model has been extensively described previously31,57,58. The maximal tumor size allowed by the Home Office license for this project and authorized by the Animal Welfare Ethical…

Continue Reading In vivo screening characterizes chromatin factor functions during normal and malignant hematopoiesis

The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma

Susanibar-Adaniya S, Barta SK. 2021 Update on diffuse large B cell lymphoma: a review of current data and potential applications on risk stratification and management. Am J Hematol. 2021;96:617–29. Article  PubMed  PubMed Central  Google Scholar  Rovira J, Valera A, Colomo L, Setoain X, Rodriguez S, Martinez-Trillos A, et al. Prognosis…

Continue Reading The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma

Mitochondrial genomic investigation reveals a clear association between species and genotypes of Lucilia and geographic origin in Australia | Parasites & Vectors

Zumpt F. Myiasis in man and animals in the old world. A textbook for physicians, veterinarians and zoologists. London: Butterworth; 1965. Google Scholar  Stevens JR, Wall R. Genetic variation in populations of the blowflies Lucilia cuprina and Lucilia sericata (Diptera: Calliphoridae). Random amplified polymorphic DNA analysis and mitochondrial DNA sequences….

Continue Reading Mitochondrial genomic investigation reveals a clear association between species and genotypes of Lucilia and geographic origin in Australia | Parasites & Vectors

ncRNA | Free Full-Text | Investigation into the Role of Long-Non-Coding RNA MIAT in Leukemia

1. Introduction Recent advances in RNA-based approaches and Next Generation Technologies have unveiled the existence of non-coding RNAs (ncRNA), transcripts that lack the ability to code for proteins [1,2]. ncRNAs typically lack an open reading frame (ORF) and are subdivided into housekeeping and regulatory transcripts. Housekeeping ncRNAs are usually 50–500…

Continue Reading ncRNA | Free Full-Text | Investigation into the Role of Long-Non-Coding RNA MIAT in Leukemia